How fortunate are we to have @kimrynrathmell.bsky.social bring her wealth of experience & outstanding leadership to @osucccjames.bsky.social @osuwexmed.bsky.social ! Welcome to #BuckeyeNation Dr. Rathmell! @osuhematology.bsky.social

The closest I’m ever going to come to a National Football Championship Trophy ! 🙏🏽 @Peletonia @Huntington_Bank @OhioStateFB Proud to be a Peletonia funded @osuhematology.bsky.social @osucccjames.bsky.social Researcher & part of #BuckeyeNation

What other kinds of presentations are there (other than fabulous ? ) Clearly, I have been attending the wrong conferences so far without fabulous presentations 😂

a nice analysis from the BEAT AML study outlining molecular characteristics of adults >60 with AML www.nature.com/articles/s41...

Hi. Books are incredibly important. Please let them be.

helpful sub-group analysis of Aza + Ven studies looking at treatment-naive t-AML and AML arising from MDS or CMML! www.nature.com/articles/s41...

Very proud to have played a role in this study with my study chair Dr. Eric Huselton from University of Rochester - please consider your patients for this study @osuhematology.bsky.social @osucccjames.bsky.social @swog.org @ash.hematology.org

If you know anyone that takes Sprycell, please let them know !!!

A great @bloodjournal.bsky.social paper by @beatalleukemia.bsky.social et al on clinical trial eligibility for patients with MDS! ashpublications.org/blood/articl...

Thrilled to see our effort on behalf of @ic_MDS group out in @BloodJournal about reducing clinical trial eligibility barriers for our MDS patients. Commentary by Lionel Ades on ‘ releasing the brake’ on eligibility criteria. @Dr_AmerZeidan #mdssm ashpublications.org/blood/article/…

Happy CD3 CD28 T Cell Stimulation Day to all who celebrate

Calling all hematologists - how are you interpreting the results of the TRAIN trial vs the SAHARA trial in patients with blood cancers & acute cerebral bleeding events ? jamanetwork.com/journals/jam... www.nejm.org/doi/full/10.... @shematologist.medsky.social @bloodman.bsky.social

Sunset & snow makes for good hunting.#springbreak

I would be the second to last one 😂

a very nice review in AJH on considerations of MPN management in women! onlinelibrary.wiley.com/doi/full/10....

👇🏾

Could adjusting a simple blood test reference range save patients unnecessary stress? Recent research highlights Duffy null-associated neutrophil count (DANC) and the risk it imposes on certain ancestral backgrounds. Enroll in the ASH course: bit.ly/duffynull #HemeSky #Hematology #MedSky

The 2025 @castleconnolly.bsky.social Exceptional Women in Medicine is out!🎉This honor celebrates🔝female physicians for their leadership & expertise. 👏 Congrats to the OSUCCCJames Heme honorees: Jennifer Woyach Uma Borate @beatalleukemia.bsky.social Alice Mims Ashley Rosko Kami Maddocks Kerry Rogers

EST to PST problems. Awake 3 hrs before #ASH24 activities start but very excited for our Scientific Workshop on DCTs & AI from 2-5 pm today! If you are a trial sponsor , investigator , statistician or involved in any clinical research- this one is ‘A must attend’ ! #DCTs

Great haiku! The excitement for #ASH24 will power us through this early morning!

Waking up before the crack of dawn EST to PST Excited for #ASH24 #ASHaiku

Our Friday Scientific Workshop on Real World DCTs in Hematology &AI has a fantastic line up of speakers : clinical trialists ( IIT PIs included) statisticians, pharma sponsors, & regulatory experts discussing all things practical about hematology DCTs - join us ! 👇🏾#ASH24

go.bsky.app/Avv8xad I made this starter pack for any myeloid malignancy academics to find others - please share & add to this !

🩸 CHIP, CCUS, & ICUS quick definitions: CHIP - leukemia-associated gene mutation w/ VAF ≥ 2% - normal blood counts - no dx of another hematologic malignancy CCUS = CHIP with ≥ 1 cytopenias ICUS ≥ 1 cytopenias + 🚫 identifiable mutation #hemesky #MedSky #IMsky

📢 Don’t miss Ohio State’s 2024 Scarlet and Gray Reception at the National ASH Meeting! 🌟 Network, connect, and celebrate with us. 🗓️ Register now: osu.az1.qualtrics.com/jfe/form/SV_8H…#ASH242#BuckeyePrided#ScarletAndGrayay

www.nejm.org/doi/full/10.... Such an important article addressing why certain groups may receive differing medical treatment including access to clinical trials.

The final version of our Blood Advances manuscript looking at sub-q decitabine in myelofibrosis is out! pubmed.ncbi.nlm.nih.gov/39250708/

Proud to be the first to follow @beatalleukemia.bsky.social on @bsky.app!!! Join me in following her for outstanding content on leukemia, science, and life!